Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.
Share and Cite
MDPI and ACS Style
NAKARANI, M.; PATEL, P.; PATEL, J.; PATEL, P.; MURTHY, R.S.R.; VAGHANI, S.S.
Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation. Sci. Pharm. 2010, 78, 345-362.
NAKARANI M, PATEL P, PATEL J, PATEL P, MURTHY RSR, VAGHANI SS.
Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation. Scientia Pharmaceutica. 2010; 78(2):345-362.
NAKARANI, Mahendra, Priyal PATEL, Jayvadan PATEL, Pankaj PATEL, Rayasa S. R. MURTHY, and Subhash S. VAGHANI.
2010. "Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation" Scientia Pharmaceutica 78, no. 2: 345-362.
Article Access Statistics
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.